User login

TRIPS waiver deadlock continues; industry cites logistics, not IP barriers

April 22, 2021 at 5:37 PM
Despite six months of discussion, a proposal to waive a swath of intellectual property obligations at the World Trade Organization to facilitate COVID-19 vaccine and therapeutics access is no closer to approval, with developed members, including the U.S., continuing to question whether it would be effective and if IP rights are indeed barriers. The answer to both questions, according to the pharmaceutical industry – and some intellectual property professionals – is no. The proposed waiver would do nothing to address...

Not a subscriber? Sign up for 30 days free access to exclusive, behind-the-scenes reporting on trade policy in the Biden era.